Liposome-based approaches for delivery of mainstream chemotherapeutics: Preparation methods, liposome designs, therapeutic efficacy

Critical Reviews in Oncogenesis

Volumn 19, Issue 3-4, 2014, Pages 177-222

  Sempkowski, Michelle ^a   Locke, Trevan ^b   Stras, Sally ^b   Zhu, Charles ^a   Sofou, Stavroula ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b The State University of New Jersey   (United States)

Author keywords

Chemotherapy; Liposomal chemotherapy; Liposomes

Indexed keywords

DOXORUBICIN; LIPOSOME; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; ENCAPSULATION; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; DOXORUBICIN; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOSOMES; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84906078450     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.2014011533     Document Type: Article

References (255)

1. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2013;66:2-25
2. Jain RK, Stylianopoulos T. Delivering nano-medicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653-664.
3. Federico Perche and Vladimir P. Torchilin, "Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting," Journal of Drug Delivery, vol. 2013, Article ID 705265, 32 pages, 2013. doi:10.1155/2013/705265
4. Sofou S. Surface-active liposomes for targeted cancer therapy. Nanomedicine. 2007;2:711-724.
5. Allen TM. Ligand-targeted therapeutics in anti-cancer therapy. Nat Rev Cancer. 2002;2:750-763.
6. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153:198-205.
7. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36-48.
8. Prabhakar U, Blakey DC, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC. Challenges and key considerations of the enhanced permeability and retention efect (EPR) for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412-2417
9. Sofou S. Surface-active liposomes for targeted cancer therapy. Nanomed. 2007;2:711-724
10. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Disc. 2005;4:145-160.
11. Torchilin V P. Targeted pharmaceutical nanocar-riers for cancer therapy and imaging. AAPS J. 2007;9:E128-E147.
12. Sturgeon RJ, Schulman SG. Electronic absorption spectra and protolytic equilibria of doxorubicin: direct spectrophotometric determination of microconstants. J Pharm Sci. 1977;66:958-961.
13. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor efects of the anthracycline antibiotics adria-mycin and daunorubicin. Biochem Pharmacol. 1999;57:727-741.
14. Hanusova V, Bousova I, Skalova L. Possibilities to increase the efectiveness of doxorubicin in cancer cells killing. Drug Metab Rev. 2011;43:540-557.
15. Di Marco A. Adriamycin (NSC-123127); Mode and mechanism of action. Cancer Chemother Rep. 1975;6:91-106.
16. Zunino F, Gambetta R, Di Marco A, Zaccara A, Luoni G. A comparison of the efects of daunomycin and adriamycin on various DNA polymerases. Cancer Res. 1975;35:754-760.
17. Momparler RL, Karon M, Siegel SE, Avila F. Efect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976;36:2891-2895.
18. Kiyomiya K, Matsuo S, Kurebe M. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sci. 1998;62:1853-1860.
19. Kiyomiya K, Matsuo S, Kurebe M. Mechanism of specifc nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-pro-teasome complex. Cancer Res. 2001;61:2467-2471.
20. Ashley N, Poulton J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun. 2009;378:450-455.
21. Osheroff N, Corbett AH, Robinson MJ. Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv Pharmacol. 1994;29b:105-126.
22. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (New York). 1984;226:466-468.
23. Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK. Predictive value of apoptosis, proliferation, HER-2, and topoisom-erase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treatment. 2005;92:69-75.
24. Lage H, Helmbach H, Dietel M, Schadendorf D. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer. 2000;82:488-491.
25. Muss HB, Tor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
26. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361-1370.
27. Tor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. erbB-2, p53, and efcacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
28. Ravdin PM. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol. 1999;26:117-123.
29. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J. Amplifcation and deletion of topoisomerase IIalpha associate with ErbB-2 amplifcation and afect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-847.
30. Skladanowski A, Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol. 1993;46:375-382.
31. Dunkern TR, Wedemeyer I, Baumgartner M, Fritz G, Kaina B. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair. 2003;2:49-60.
32. Ruiz-Ruiz C, Robledo G, Cano E, Redondo JM, Lopez-Rivas A. Characterization of p53-medi-ated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. J Biol Chem. 2003;278:31667-31675.
33. Inoue A, Narumi K, Matsubara N, Sugawara S, Saijo Y, Satoh K, Nukiwa T. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett. 2000;157:105-112.
34. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de Te H. Efect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet. 2002;360:852-854.
35. Clementi ME, Giardina B, Di Stasio E, Mordente A, Misiti F. Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 2003;23:2445-2450.
36. Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta. 2002;1588:94-101.
37. Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE. Diferential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry. 1987;26:3776-3781.
38. Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 1983;43:4543-4551.
39. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem. 2008;6:278-281.
40. Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res. 1989;49:3844-3848.
41. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-905.
42. Abdel-aleem S, el-Merzabani MM, Sayed-Ahmed M, Taylor DA, Lowe JE. Acute and chronic efects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol. 1997;29:789-797.
43. Ondrias K, Borgatta L, Kim DH, Ehrlich BE. Biphasic efects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. Circ Res. 1990;67:1167-1174.
44. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols R. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol. 1985;34:2583-2586.
45. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987;84:3004-3008.
46. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C. Reduced cardiotox-icity and comparable efcacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxoru-bicin for frst-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
47. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as frst-line therapy of meta-static breast carcinoma. Cancer. 2002;94:25-36.
48. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta. 1986;857:123-126.
49. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60:1197-1201.
50. Li X, Cabral-Lilly D, Janof AS, Perkins WR. Complexation of Internalized Doxorubicin into Fiber Bundles Afects its Release Rate from Liposomes. J Liposome Res. 2000;10:15-27.
51. Li X, Hirsh DJ, Cabral-Lilly D, Zirkel A, Gruner SM, Janof AS, Perkis WR. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta. 1998;1415:23-40.
52. Li L, ten Hagen TL, Schipper D, Wijnberg TM, van Rhoon GC, Eggermont AM, Lindner L H, Koning G A. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release. 2010;143:274-279.
53. Cheung BC, Sun TH, Leenhouts JM, Cullis PR. Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. Biochim Biophys Acta. 1998;1414:205-216.
54. Abraham SA, Edwards K, Karlsson G, MacIntosh S, Mayer LD, McKenzie C, Bally MB. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophysa Acta. 2002;1565:41-54.
55. Bolotin EM, Cohen R, Bar LK, Emanuel N, Ninio S, Barenholz Y, Lasic DD. Ammonium sulfate gradients for efcient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res. 1994;4:455-479.
56. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efcient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151:201-215.
57. Fritze A, Hens F, Kimpfer A, Schubert R, Peschka-Suss R. Remote loading of doxorubi-cin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006;1758:1633-1640.
58. Alaouie AM, Sofou S. Liposomes with triggered content release for cancer therapy. J Biomed Nanotechnol. 2008;4:234-244.
59. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. Sterically stabilized lipo-somes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta. 1991;1070:187-192.
60. Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs. 2011;71:2531-2558.
61. Jiang W, Lionberger R, Yu LX. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis. 2011;3:333-344.
62. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxo-rubicin. Clin Pharmacokinet. 2003;42:419-436.
63. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 2006;24:2773-2778.
64. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997;15:3185-3191.
65. Gabizon AA. Pegylated liposomal doxoru-bicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19:424-436.
66. Swenson CE, Perkins WR, Roberts P, Janof AS. Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate). Breast. 2001;10, Supplement 2:1-7.
67. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta. 1992;1113:171-199.
68. Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson CE. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol. 2004;54:514-524.
69. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in frst-line treatment of meta-static breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs. 2006;17:587-595.
70. Moura SAL, Lima LDC, Andrade SP, Da Silva-Cunha A, Orefce RL, Ayres E, Da Silva GR. Local drug delivery system: Inhibition of infammatory angiogenesis in a murine sponge model by dexamethasone-loaded polyurethane implants. J Pharm Sci. 2011;100:2886-2895.
71. Swenson CE, Bolcsak LE, Batist G, Guthrie TH, Jr., Tkaczuk KH, Boxenbaum H, Welles L, Chow SC, Bhamra R, Chaikin P. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophospha-mide in patients with metastatic breast cancer. Anticancer Drugs. 2003;14:239-246.
72. Hong RL, Tseng YL. Phase I and pharmacoki-netic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer. 2001;91:1826-1833.
73. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythro-dysesthesia ('hand-foot' syndrome). Ann Oncol. 2007;18:1159-1164.
74. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Correlation of toxicity with pharmaco-kinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89:1037-1047.
75. Cortes J, Di Cosimo S, Climent MA, Cortes-Funes H, Lluch A, Gascon P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodriguez CA, Trigo JM, Vazquez J, Reguiero P, Dorado JF, Baselga J. Nonpegylated liposo-mal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res. 2009;15:307-314.
76. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW. Reduced car-diotoxicity and preserved antitumor efcacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444-1454.
77. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specifc and efcient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003;63:3154-3161.
78. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Epidermal growth factor receptor-targeted immunoliposomes signifcantly enhance the efcacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65:11631-11638.
79. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C. Tolerability, safety, pharmacokinetics, and efcacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 2012;13:1234-1241.
80. Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs. 2000;11:123-127.
81. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjopoulos D. Termosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys. 1996;36:1177-1187.
82. Magin RL, Niesman MR. Temperature-dependent drug release from large unilamellar liposomes. Cancer Drug Deliv. 1984;1:109-117.
83. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science (New York). 1978;202:1290-1293.
84. Li L, ten Hagen TL, Hossann M, Suss R, van Rhoon GC, Eggermont AM, Haemmerich D, Koning GA. Mild hyperthermia triggered doxorubicin release from optimized stealth ther-mosensitive liposomes improves intratumoral drug delivery and efcacy. J Control Release. 2013;168(2):142-150.
85. Kong G, Braun RD, Dewhirst MW. Hyperthermia Enables Tumor-specific Nanoparticle Delivery: Efect of Particle Size. Cancer Res. 2000;60:4440-4445.
86. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efcacy of liposomes and hyperther-mia in a human tumor xenograft model: Importance of triggered drug release. Cancer Res. 2000;60:6950-6957.
87. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor efects. J Natl Cancer Inst. 2007;99:53-63.
88. Needham D, Dewhirst MW. Te development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev. 2001;53:285-305.
89. Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Yuan F, Needham D, Viglianti BL, Dewhirst MW. Comparative efects of thermosensitive doxorubicin-containing liposomes and hyper-thermia in human and murine tumours. Int J Hypertherm. 2010;26:485-498.
90. Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng KK, Eugeni M, Seidel G, Dromi S, Neeman Z, Kolf M, Black CD, Prabhakar R, Libutti SK. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Intervent Radiol. 2012;23:248-255.
91. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased micro-vascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 1993;53:3765-3770.
92. Pan XQ, Wang H, Lee RJ. Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res. 2002;22:1629-1633.
93. Rossin R, Pan D, Qi K, Turner JL, Sun X, Wooley KL, Welch MJ. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med. 2005;46:1210-1218.
94. Mellman I, Fuchs R, Helenius A. Acidifcation of the endocytic and exocytic pathways. Annu Rev Biochem. 1986;55:663-700.
95. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995;13:527-537.
96. Ellens H, Bentz J, Szoka FC. pH-induced destabilization of phosphatidylethanolamine-containing liposomes: role of bilayer contact. Biochemistry. 1984;23:1532-1538.
97. Slepushkin VA, Simoes S, Dazin P, Newman MS, Guo LS, Pedroso de Lima MC, Duzgunes N. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J Biol Chem. 1997;272:2382-2388.
98. Ishida T, Okada Y, Kobayashi T, Kiwada H. Development of pH-sensitive lipo-somes that efciently retain encapsulated doxorubicin (DXR) in blood. Int J Pharm. 2006;309:94-100.
99. Ishida T, Kirchmeier MJ, Moase EH, Zalipsky S, Allen TM. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta. 2001;1515:144-158.
100. Samsonov AV, Mihalyov I, Cohen FS. Characterization of cholesterol-sphingomyelin domains and their dynamics in bilayer membranes. Biophys J. 2001;81:1486-1500.
101. Dietrich C, Bagatolli LA, Volovyk ZN, Tompson NL, Levi M, Jacobson K, Gratton E. Lipid rafts reconstituted in model membranes. Biophys J. 2001;80:1417-1428.
102. Feigenson GW, Buboltz J T. Ternary phase diagram of dipalmitoyl-PC/dilauroyl-PC/choles-terol: Nanoscopic domain formation driven by cholesterol. Biophys J. 2001;80:2775-2788.
103. Bajagur Kempegowda G, Karve S, Bandekar A, Adhikari A, Khaimchayev T, Sofou S. pH-dependent formation of lipid heterogeneities controls surface topography and binding reactivity in functionalized bilayers. Langmuir. 2009;25:8144-8151.
104. Karve S, Bajagur Kempegowda G, Sofou S. Heterogeneous domains and membrane permeability in phosphatidylcholine- phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch. Langmuir. 2008;24:5679-5688.
105. Boggs JM. Lipid intermolecular hydrogen bonding: infuence on structural organization and membrane function. Biochim Biophys Acta. 1987;906:353-404.
106. Bandekar A, Karve S, Chang MY, Mu Q, Rotolo J, Sofou S. Antitumor efcacy following the intracellular and interstitial release of liposomal doxorubicin. Biomaterials. 2012;33:4345-4352.
107. Bhagat M, Sofou S. Membrane heterogeneities and fusogenicity in phosphatidylcholine- phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch. Langmuir. 2010;26:1666-1673.
108. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49:4373-4384.
109. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732-6740.
110. Song S, Liu D, Peng J, Sun Y, Li Z, Gu JR, Xu Y. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008;363:155-161.
111. Schifelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G. Anti-tumor efcacy of tumor vasculature-targeted liposomal doxoru-bicin. J Control Release. 2003;91:115-122.
112. Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release. 2008;126:50-58.
113. Janssen AP, Schifelers RM, ten Hagen TL, Koning GA, Schraa AJ, Kok RJ, Storm G, Molema G. Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int J Pharm. 2003;254:55-58.
114. Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J, Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modifed PEG liposomes. Int J Pharm. 2007;342:194-200.
115. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. Sterically stabilized anti-HER2 immunolipo-somes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997;36:66-75.
116. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, Benz CC. Development of anti-p185HER2 immunoli-posomes for cancer therapy. Proc Natl Acad Sci U S A. 1995;92:1327-1331.
117. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efcacy attributable to targeted delivery. Clin Cancer Res. 2002;8:1172-1181.
118. Tai W, Mahato R, Cheng K. Te role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146:264-275.
119. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
120. Muss HB, Tor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
121. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ. Impact of tumor HER2/ERBB2 expression level on HER2-argeted liposomal doxorubicin-mediated drug delivery: Multiple low-afnity interactions lead to a threshold efect. Mol Cancer Ter. 2013;12:1816-1828.
122. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarri-ers to improve drug delivery to brain tumors. Biomaterials. 2009;30:3986-3995.
123. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP. "SMART" drug delivery systems: Double-Targeted pH-responsive pharmaceutical nano-carriers. Bioconjug Chem. 2006;17:943-949.
124. 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor-expressing breast carcinomas. Clin Cancer Res. 2007;13:6070-6079.
125. Bandekar A, Zhu C, Gomez A, Menzenski MZ, Sempkowski M, Sofou S. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo. Mol Pharm. 2013;10:152-160.
126. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium. 2006;13:113-135.
127. Ellis LM. A targeted approach for antiangio-genic therapy of metastatic human colon cancer. Am Surg. 2003;69:3-10.
128. Honn K, Tang D. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metast Rev. 1992;11:353-375.
129. Jayne DG, Heath RM, Dewhurst O, Scott N, Guillou PJ. Extracellular matrix proteins and chemoradiotherapy: alpha5beta1 integrin as a predictive marker in rectal cancer. Eur J Surg Oncol. 2002;28:30-36.
130. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90:561-565.
131. Livant DL. Targeting invasion induction as a therapeutic strategy for the treatment of cancer. Curr Cancer Drug Targets. 2005;5:489-503.
132. Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A, Baluk P, Favre CJ, Jefry U, Murray R, McDonald DM. Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol. 2005;167:193-211.
133. Serini G, Napione L, Arese M, Bussolino F. Besides adhesion: new perspectives of integrin functions in angiogenesis. Cardiovasc Res. 2008;78:213-222.
134. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res. 2006;312:651-658.
135. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarthy MF, Bucana CD, Mazar AP, Ellis LM. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003;104:496-503.
136. Shrof K, Kokkoli E. PEGylated liposomal doxorubicin targeted to α5b1-expressing MDA-MB-231 breast cancer cells. Langmuir. 2012;28:4729-4736.
137. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem. 2010;53:6811-6824.
138. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233:134-144.
139. Pan XQ, Wang H, Lee RJ. Antitumor activity of folate receptor-targeted liposomal doxorubi-cin in a KB oral carcinoma murine xenograft model. Pharm Res. 2003;20:417-422.
140. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269:3198-3204.
141. Lee RJ, Wang S, Turk MJ, Low PS. The efects of pH and intraliposomal bufer strength on the rate of liposome content release and intracel-lular drug delivery. Biosci Rep. 1998;18:69-78.
142. Parton RG, Simons K. Te multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8:185-194.
143. Stan RV. Structure of caveolae. Biochim Biophys Acta. 2005;1746:334-348.
144. Mamasheva E, O'Donnell C, Bandekar A, Sofou S. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin. Mol Pharm. 2011;8:2224-2232.
145. Koudelka S, Turanek J. Liposomal paclitaxel formulations. J Control Release. 2012;163:322-334.
146. Lowe J, Li H, Downing KH, Nogales E. Refned structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol. 2001;313:1045-1057.
147. Rao S, Krauss NE, Heerding JM, Swindell CS, Ringel I, Orr GA, Horwitz SB. 3'-(p-azido-benzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem. 1994;269:3132-3134.
148. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004-1014.
149. Schif PB, Horwitz SB. Taxol stabilizes micro-tubules in mouse fbroblast cells. Proc Natl Acad Sci U S A. 1980;77:1561-1565.
150. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82:1247-1259.
151. Andre N, Braguer D, Brasseur G, Goncalves A, Lemesle-Meunier D, Guise S, Jordan MA, Briand C. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res. 2000;60:5349-5353.
152. Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C, Mozzetti S, Gallo D, Persico M, Fattorusso C, Campiani G, Scambia G. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009;69:6906-6914.
153. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179-192.
154. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol(R)). Semin Oncol. 1993;20:1-15.
155. Bernsdorf C, Reszka R, Winter R. Interaction of the anticancer agent Taxol (paclitaxel) with phospholipid bilayers. J Biomed Mater Res. 1999;46:141-149.
156. Zhao L, Feng SS. Efects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes. J Colloid Interface Sci. 2004;274:55-68.
157. Kan P, Tsao CW, Wang AJ, Su WC, Liang HF. A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer efect. J Drug Deliv. 2011;2011:629234.
158. Biswas S, Dodwadkar NS, Deshpande P P, Torchilin V P. Liposomes loaded with paclitaxel and modifed with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor efects in vitro and in vivo. J Control Release. 2012;159:393-402.
159. Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials. 2012;33:6758-6768.
160. Jiang T, Zhang Z, Zhang Y, Lv H, Zhou J, Li C, Hou L, Zhang Q. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials. 2012;33:9246-9258.
161. Joshi N, Saha R, Shanmugam T, Balakrishnan B, More P, Banerjee R. Carboxymethyl-chitosan-tethered lipid vesicles: hybrid nanoblanket for oral delivery of paclitaxel. Biomacromolecules. 2013;14:2272-2282.
162. Kulshrestha P, Gogoi M, Bahadur D, Banerjee R. In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia. Colloids Surf B. 2012;96:1-7.
163. Luo L-M, Huang Y, Zhao B-X, Zhao X, Duan Y, Du R, Yu K-F, Song P, Zhao Y, Zhang X, Zhang Q. Anti-tumor and anti-angiogenic efect of metronomic cyclic NGR-modifed liposomes containing paclitaxel. Biomaterials. 2013;34:1102-1114.
164. Solomon MA, Shah AA, D'Souza GGM. In Vitro assessment of the utility of stearyl tri-phenyl phosphonium modifed liposomes in overcoming the resistance of ovarian carcinoma Ovcar-3 cells to paclitaxel. Mitochondrion. 2013;13:464-472.
165. Zhang Q, Tang J, Fu L, Ran R, Liu Y, Yuan M, He Q. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials. 2013;34:7980-7993.
166. Zhou J, Zhao W-Y, Ma X, Ju R-J, Li X-Y, Li N, Sun M-G, Shi J-F, Zhang C-X, Lu W-L. Te anticancer efcacy of paclitaxel liposomes modifed with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 2013;34:3626-3638.
167. Liang X, Li X, Jing L, Xue P, Jiang L, Ren Q, Dai Z. Design and synthesis of lipidic organoalkoxysilanes for the self-assembly of liposomal nanohybrid cerasomes with controlled drug release properties. Chemistry. 2013;19:16113-16121.
168. Yan F, Li L, Deng Z, Jin Q, Chen J, Yang W, Yeh C-K, Wu J, Shandas R, Liu X, Zheng H. Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers. J Control Release. 2013;166:246-255.
169. Ansell SM, Johnstone SA, Tardi PG, Lo L, Xie S, Shu Y, Harasym TO, Harasym NL, Williams L, Bermudes D, Liboiron BD, Saad W, Prud'Homme RK, Mayer LD. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydropho-bicity of prodrug conjugates. J Med Chem. 2008;51:3288-3296.
170. Wu H, Zhu L, Torchilin VP. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials. 2013;34:1213-1222.
171. Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmaco-kinetics, and toxicological evaluation. Eur J Pharm Biopharm. 2011;79:276-284.
172. Soepenberg O, Sparreboom A, de Jonge MJ, Planting AS, de Heus G, Loos WJ, Hartman CM, Bowden C, Verweij J. Real-time phar-macokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. Eur J Cancer (Oxford, England: 1990). 2004;40:681-688.
173. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol. 2001;47:309-318.
174. Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol. 2002;20:574-581.
175. Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR. Pharmacokinetic/phar-macodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res. 2008;14:5856-5863.
176. Xu FJ, Pirollo KF, Chang EH. Tumor-targeted p53-gene therapy enhances the efcacy of conventional chemo/radiotherapy. J Control Release. 2001;74:115-128.
177. Fasol U, Frost A, Buchert M, Arends J, Fiedler U, Scharr D, Scheuenpfug J, Mross K. Vascular and pharmacokinetic efects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann Oncol. 2012;23:1030-1036.
178. Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993;11:2127-2135.
179. Strieth S, Dunau C, Michaelis U, Jager L, Gellrich D, Wollenberg B, Dellian M. Phase I/II clinical study on safety and antivascular efects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer. Head Neck. 2014;36:976-984
180. Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U, Jauch KW, Bruns CJ, Dellian M. Vascular targeting by EndoTAG-1 enhances therapeutic efcacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer J. 2010;126:1235-1245.
181. Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U, Berghaus A, Dellian M. Paclitaxel encapsulated in cationic lipo-somes increases tumor microvessel leakiness and improves therapeutic efcacy in combination with Cisplatin. Clin Cancer Res. 2008;14:4603-4611.
182. Löhr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Folsch UR, Jager D, Osinsky D, Prausova J, Schmidt WE, Lutz M P. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012;23:1214-1222.
183. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698-699.
184. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385-386.
185. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573-584.
186. Liu D, He C, Wang AZ, Lin W. Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomed. 2013;8:3309-3319.
187. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 1993;67:1171-1176.
188. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper infux transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006;70:1390-1394.
189. Ishida S, Lee J, Tiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002;99:14298-14302.
190. Burger KN, Stafhorst RW, de Vijlder HC, Velinova MJ, Bomans PH, Frederik PM, de Kruijf B. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med. 2002;8:81-84.
191. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Terapeut. 1987;34:155-166.
192. Kelland LR. Preclinical perspectives on platinum resistance. Drugs. 2000;59 Suppl 4:1-8; discussion 37-8.
193. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-7279.
194. Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics: Integr Biometal Sci. 2009;1:280-291.
195. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307-320.
196. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T, Akiyama S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 2000;60:1312-1316.
197. Miyashita H, Nitta Y, Mori S, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Kawamura H, Sato A, Morikawa H, Motegi K, Takebayashi Y. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemo-resistance marker in human oral squamous cell carcinoma treated with cisplatin. Oral Oncol. 2003;39:157-162.
198. Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol. 1993;15:191-219.
199. Crul M, van Waardenburg RC, Beijnen JH, Schellens JH. DNA-based drug interactions of cisplatin. Cancer Treat Rev. 2002;28:291-303.
200. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv. 2012;2012:581363.
201. Zisman N, Dos Santos N, Johnstone S, Tsang A, Bermudes D, Mayer L, Tardi P. Optimizing liposomal cisplatin efcacy through membrane composition manipulations. Chemother Res Practice. 2011;2011:213848.
202. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm. 2008;349:38-46.
203. Junior AD, Mota LG, Nunan EA, Wainstein AJ, Wainstein AP, Leal AS, Cardoso VN, De Oliveira MC. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. Life Sci. 2007;80:659-664.
204. Peleg-Shulman T, Gibson D, Cohen R, Abra R, Barenholz Y. Characterization of steri-cally stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim Biophys Acta. 2001;1510:278-291.
205. Chanda J, Bandyopadhyay S. Perturbation of phospholipid bilayer properties by ethanol at a high concentration. Langmuir. 2006;22:3775-3781.
206. Barchfeld GL, Deamer DW. Alcohol efects on lipid bilayer permeability to protons and potassium: relation to the action of general anesthetics. Biochim Biophys Acta. 1988;944:40-48.
207. Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, Talmon Y, Kost J, Barenholz Y. Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir. 2007;23:4019-4025.
208. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efciently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 2002;62:4282-4288.
209. Kuang Y, Liu J, Liu Z, Zhuo R. Cholesterol-based anionic long-circulating cisplatin lipo-somes with reduced renal toxicity. Biomaterials. 2012;33:1596-1606.
210. Karita M, Tsuchiya H, Kawahara M, Kasaoka S, Tomita K. Te antitumor efect of liposome-encapsulated cisplatin on rat osteosarcoma and its enhancement by cafeine. Anticancer Res. 2008;28:1449-1457.
211. Lv Q, Li LM, Han M, Tang XJ, Yao JN, Ying XY, Li FZ, Gao JQ. Characteristics of sequential targeting of brain glioma for transferrin-modifed cisplatin liposome. Int J Pharm. 2013;444:1-9.
212. Kakinuma K, Tanaka R, Takahashi H, Watanabe M, Nakagawa T, Kuroki M. Targeting chemotherapy for malignant brain tumor using thermosensitive liposome and localized hyper-thermia. J Neurosurg. 1996;84:180-184.
213. Huo T, Barth RF, Yang W, Nakkula RJ, Koynova R, Tenchov B, Chaudhury AR, Aguis L, Boulikas T, Elleaume H, Lee RJ. Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats. PloS One. 2012;7:e48752.
214. Boulikas T. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Invest Drugs. 2009;18:1197-1218.
215. Hirai M, Minematsu H, Hiramatsu Y, Kitagawa H, Otani T, Iwashita S, Kudoh T, Chen L, Li Y, Okada M, Salomon DS, Igarashi K, Chikuma M, Seno M. Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. Int J Pharm. 2010;391:274-283.
216. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative phar-macokinetics, tissue distribution, and therapeutic efectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43:1-7.
217. Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs. 1999;10:911-920.
218. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol. 2004;53:329-336.
219. de Carvalho Maroni L, de Oliveira Silveira AC, Leite EA, Melo MM, de Carvalho Ribeiro AF, Cassali GD, de Souza CM, Souza-Fagundes EM, Caldas IR, Araujo MS, Martins-Filho OA, de Oliveira MC, Teixeira-Carvalho A. Antitumor efectiveness and toxicity of cispl-atin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor. Exp Biol Med. 2012;237:973-984.
220. Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery--a general review. Expert Opin Drug Deliv. 2004;1:37-56.
221. Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y. Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release. 2009;137:63-68.
222. Chiarugi VP, Dietrich CP. Sulfated muco-polysaccharides from normal and virus transformed rodent fibroblasts. J Cell Physiol. 1979;99:201-206.
223. Bumol TF, Reisfeld RA. Unique glycoprotein-proteoglycan complex defned by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A. 1982;79:1245-1249.
224. Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol. 2002;49:201-210.
225. Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, Woolley PV. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol. 1980;5:21-26.
226. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM, Stewart JS. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol. 2001;12:493-496.
227. White SC, Lorigan P, Margison GP, Margison JM, Martin F, Tatcher N, Anderson H, Ranson M. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006;95:822-828.
228. Seetharamu N, Kim E, Hochster H, Martin F, Muggia F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res. 2010;30:541-545.
229. de Jonge MJ, Slingerland M, Loos WJ, Wiemer EA, Burger H, Mathijssen RH, Kroep JR, de Hollander MA, van der Biessen D, Lam MH, Verweij J, Gelderblom H. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur J Cancer (Oxford, England: 1990). 2010;46:3016-3021.
230. Koukourakis MI, Giatromanolaki A, Pitiakoudis M, Kouklakis G, Tsoutsou P, Abatzoglou I, Panteliadou M, Sismanidou K, Sivridis E, Boulikas T. Concurrent liposomal cisplatin (Lipo-platin), 5-fuorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Int J Radiat Oncol Biol Phys. 2010;78:150-155.
231. Boulikas T. Molecular mechanisms of cis-platin and its liposomally encapsulated form, Lipoplatin. Lipoplatin as a chemotherapy and antiangiogenesis drug. Cancer Ther. 2007;5:351-376.
232. Stathopoulos GP, Antoniou D, Dimitroulis J, Michalopoulou P, Bastas A, Marosis K, Stathopoulos J, Provata A, Yiamboudakis P, Veldekis D, Lolis N, Georgatou N, Toubis M, Pappas Ch, Tsoukalas G. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol. 2010;21:2227-2232.
233. Froudarakis ME, Pataka A, Pappas P, Anevlavis S, Argiana E, Nikolaidou M, Kouliatis G, Pozova S, Marselos M, Bouros D. Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer. 2008;113:2752-2760.
234. Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, Viliotou V, Stathopoulos JG. Pharmacokinetics and adverse reactions of a new liposomal cis-platin (Lipoplatin): phase I study. Oncol Rep. 2005;13:589-595.
235. Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S, Politis N, Karanikas C, Kosmas C. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as frst line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer. 2010;68:240-247.
236. Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol. 2011;68:945-950.
237. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res. 2005;25:3031-3039.
238. Farhat FS, Temraz S, Kattan J, Ibrahim K, Bitar N, Haddad N, Jalloul R, Hatoum HA, Nsouli G, Shamseddine AI. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer. Clin Breast Cancer. 2011;11:384-389.
239. Marty M, Extra JM, Dieras V, Giacchetti S, Ohana S, Espie M. A review of the antitumour activity of vinorelbine in breast cancer. Drugs. 1992;44 Suppl 4:29-35; discussion 66-9.
240. Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicholson S, Peters GJ, Postmus PE. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res. 2007;13:2414-2421.
241. Chou AJ, Gupta R, Bell MD, Riewe KO, Meyers PA, Gorlick R. Inhaled lipid cispla-tin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediat Blood Cancer. 2013;60:580-586.
242. Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, Kevric M, Jundt G, Kuhne T, Maas R, Schwarz R, Zoubek A, Jurgens H. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27:557-565.
243. Harrap KR. Preclinical studies identifying car-boplatin as a viable cisplatin alternative. Cancer Treat Rev. 1985;12 Suppl A:21-33.
244. Cassidy J, Misset JL. Oxaliplatin-related side efects: characteristics and management. Semin Oncol. 2002;29:11-20.
245. Hillerdal G, Sorensen JB, Sundstrom S, Riska H, Vikstrom A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Torac Oncol. 2008;3:1325-1331.
246. Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as frst line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer 2006, 6:202 doi:10.1186/1471-2407-6-202
247. Chaudhury A, Das S, Bunte RM, Chiu GN. Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. Int J Nanomed. 2012;7:739-751.
248. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147-162.
249. Pan X, Lee RJ. Tumour-selective drug delivery via folate receptor-targeted liposomes. Expert Opin Drug Deliv. 2004;1:7-17.
250. Upadhyay AK, Ajay AK, Singh S, Bhat MK. Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Current Cancer Drug Targets. 2008;8:741-752.
251. Singh S, Upadhyay AK, Ajay AK, Bhat MK. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. FEBS Lett. 2007;581:289-295.
252. Chaudhury A, Tan BJ, Das S, Chiu GN. Increased ERK activation and cellular drug accumulation in the enhanced cytotoxicity of folate receptor-targeted liposomal carboplatin. Int J Oncol. 2012;40:703-710.
253. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993;53:5970-5976.
254. Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K. Efective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm. 2008;346:143-150.
255. Tippayamontri T, Kotb R, Paquette B, Sanche L. Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest New Drugs. 2011;29:1321-1327.